Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound
paclitaxel in patients with platinum-resistant recurrent ovarian cancer.